AstraZeneca bets on new cancer treatments with $2 billion Fusion Pharma purchase

The deal is AstraZeneca#39;s second this month after it agreed last week to buy Amolyt Pharma for $1.05 billion to shore up its rare disease portfolio.

Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *